Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Anavalin - SFDA Drug Approval Details

Approvals/SFDA/Anavalin

Authorized

GENERIC

Anavalin

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: 9d02436319cd2343
Company: Unknown
Type: Generic

Approval Details

Approval Id: 9d02436319cd2343
Drug Approval Sfda Name: Anavalin
Trade Name: Anavalin
Generic Name: CABAZITAXEL
Register Number: 0102244830
Register Year: 2024
Drug Type: Generic
Route Of Administration: Intravenous use
Package Type: Vial
Package Size: 1
Size: 6
Size Unit: ml
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: do not store above 30°c
Shelf Life: 24 Months
Distribution Site: Hospital
Description Code: 7000000186-10-100000073871
Price: 11278.35

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

9d02436319cd2343

Type

Generic

Back to SFDA Approvals